ArticleTissue engineering. Part A2011
A tissue-engineered muscle repair construct for functional restoration of an irrecoverable muscle injury in a murine model.
Article in Tissue engineering. Part A, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 184 citations in OpenAlex.
- Duchenne muscular dystrophy: from gene to gene-ius therapies.Skeletal muscle · 2026Review
- Comparison of physical, mechanical and biological properties of a porcine urinary bladder acellular matrix collagen membrane with six other collagen membranes of animal origin.BMC oral health · 2026Article
- Bioinspired hydrogel-based regenerative engineering strategies for the structural and functional regeneration of skeletal muscles following volumetric muscle loss.Regenerative biomaterials · 2026Review
- Bifunctional adECM bioscaffold with STIM1-ASCs and IGF-2 promotes functional masseter VML repair via myogenesis and fibrosis suppression.Bioactive materials · 2025Article
- Estrogen rescues muscle regeneration impaired by DUX4 in a humanized xenograft mouse model.Cell death & disease · 2025Article
- Engineering Assembloids to Mimic Graft-Host Skeletal Muscle Interaction.Advanced healthcare materials · 2025Article
- Unveiling the Potential of Bioactive Glass in Volumetric Muscle Loss Regeneration.Materials (Basel, Switzerland) · 2025Review
- Impact of Passaging Primary Skeletal Muscle Cell Isolates on the Engineering of Skeletal Muscle.Tissue engineering. Part A · 2025Article
- Current Methodologies for Inducing Aligned Myofibers in Tissue Constructs for Skeletal Muscle Tissue Regeneration.Advances in wound care · 2025Review
- Placenta-Derived Mesenchymal Stromal-Like Cells Promote 3D-Engineered Muscle Tissue Differentiation and Vessel Network Maturation.Small science · 2024Article
- Engineering interfacial tissues: The myotendinous junction.APL bioengineering · 2024Review
- Impact of Human Recombinant Irisin on Tissue-Engineered Skeletal Muscle Structure and Function.Tissue engineering. Part A · 2024Article
- Nano-biomaterials and advanced fabrication techniques for engineering skeletal muscle tissue constructs in regenerative medicine.Nano convergence · 2023Review
- In situ forming biomaterials as muscle void fillers for the provisional treatment of volumetric muscle loss injuries.Materials today. Bio · 2023Article
- Long-term longitudinal study on swine VML model.Biology direct · 2023Article
- Transcriptome profiling of a synergistic volumetric muscle loss repair strategy.BMC musculoskeletal disorders · 2023Article
- Cellulose and Lignin-Derived Scaffold and Their Biological Application in Tissue Engineering, Drug Delivery, and Wound Healing: A Review.Cell journal · 2023Article
- Local IL-10 delivery modulates the immune response and enhances repair of volumetric muscle loss muscle injury.Scientific reports · 2023Article
- Redesigning of 3-Dimensional Vascular-Muscle Structure Using ADSCs/HUVECs Co-Culture and VEGF on Engineered Skeletal Muscle ECM.Cell journal · 2022Article
- Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
There are no effective clinical treatments for volumetric muscle loss (VML) resulting from traumatic injury, tumor excision, or other degenerative diseases of skeletal muscle. The goal of this study was to develop and characterize a more clinically relevant tissue-engineered muscle repair (TE-MR) construct for functional restoration of a VML injury in the mouse lattissimus dorsi (LD) muscle. To this end, TE-MR constructs developed by seeding rat myoblasts on porcine bladder acellular matrix were preconditioned in a bioreactor for 1 week and implanted in nude mice at the site of a VML injury created by excising 50% of the native LD. Two months postinjury and implantation of TE-MR, maximal tetanic force was ∼72% of that observed in native LD muscle. In contrast, injured LD muscles that were not repaired, or were repaired with scaffold alone, produced only ∼50% of native LD muscle force after 2 months. Histological analyses of LD tissue retrieved 2 months after implantation demonstrated remodeling of the TE-MR construct as well as the presence of desmin-positive myofibers, blood vessels, and neurovascular bundles within the TE-MR construct. Overall, these encouraging initial observations document significant functional recovery within 2 months of implantation of TE-MR constructs and provide clear proof of concept for the applicability of this technology in a murine VML injury model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.